摘要
目的:观察接骨药丸防治人工股骨头置换术后假体周围骨质疏松的临床疗效。方法:将72例需行人工股骨头置换术的股骨颈骨折患者随机分为2组,每组36例。人工股骨头置换术后,治疗组患者口服接骨药丸治疗,连续服用2个月;对照组患者口服活性维生素D治疗,连续服用2个月。分别于服药前和服药2个月后测定2组患者的股骨骨密度、血清碱性磷酸酶含量及疼痛程度分级,并根据以上3个指标制定疗效评定标准,评定患者的临床综合疗效。结果:①骨密度。治疗前2组患者骨密度比较,差异无统计学意义(t=-0.079,P=0.937);治疗后2组患者骨密度均增高[(0.449±0.060)g·cm-2,(0.544±0.072)g·cm-2,t=8.638,P=0.000;(0.450±0.058)g·cm-2,(0.507±0.069)g·cm-2,t=6.107,P=0.000],治疗组增高更明显[(0.095±0.066)g·cm-2,(0.057±0.056)g·cm-2,t=2.654,P=0.038]。②血清碱性磷酸酶含量。治疗前2组患者血清碱性磷酸酶含量比较,差异无统计学意义(t=-0.135,P=0.893);治疗后2组患者血清碱性磷酸酶含量均增高[(8.080±0.498)μg·L-1,(9.090±0.452)μg·L-1,t=9.770,P=0.000;(8.096±0.500)μg·L-1,(8.644±0.408)μg·L-1,t=6.495,P=0.000],治疗组增高更明显[(1.010±0.618)μg·L-1,(0.549±0.507)μg·L-1,t=3.463,P=0.001]。③临床综合疗效。治疗组显效12例、有效22例、无效2例,对照组显效6例、有效21例、无效9例,治疗组临床综合疗效优于对照组(治疗组=31.33,对照组=41.67,Z=-2.390,P=0.017)。结论:接骨药丸可明显提高股骨头置换术后患者股骨骨密度和血清碱性磷酸酶含量,防治假体周围骨质疏松的疗效优于活性维生素D。
Objective： To observe the curative effect of JIEGUYAO pill in the prevention of periprosthetic osteoporosis after hip hemiar- throplasty. Methods： Seventy - two patients with femoral neck fracture who needed hip hemiarthroplasty were randomly divided into treat- ment group and control group, 36 cases in each group. After the operation, the patients in treatment group were administered with JIEGUYAO pills for 2 months, while the others in control group were administered with activated vitamin D for 2 months. Femoral bone min- eral density（ BMD ） , alkaline phosphatase （ALP）contents and pain degrees were determined before and after the treatment. Based on the de- termination results, the total clinical curative effects were evaluated according to the self - designed evaluation standard. Results ： There was no statistical difference in the femoral BMD between the 2 groups before the treatment （t = -0. 079, P = 0. 937 ） ;while the femoral BMD in- creased in both of the 2 groups after the treatment（0. 449 ＋/-0. 060 vs 0. 544 ＋/-0. 072 g/em （2）, t = 8. 638, P = 0. 000;0. 450 ＋/- 0. 058 vs 0.507 ＋/- 0. 069 g/cm （ 2 ） , t = 6. 107, P = 0. 000 ） , and the femoral BMD increased more significantly in the treatment group （0.095 ＋/-0.066 vs 0.057 ＋/-0. 056 g/cm（ 2 ） ,t = 2. 654 ,P = 0. 038 ）. There was no statistical difference in the ALP contents between the 2 groups before the treatment（t = -0. 135 ,P =0. 893） ;while the ALP contents increased in both of the 2 groups after the treatment （ 8. 080 ＋/- 0. 498 vs 9. 090 ＋/- 0. 452 μg/L, t = 9. 770, P = 0.000 ; 8. 096 ＋/- 0. 500 vs 8. 644 ＋/- 0. 408 μg/L, t = 6. 495, P = 0. 000 ）, and the ALP contents increased more significantly in the treatment group （ 1. 010 ＋/-0. 618 vs 0. 549 ＋/-0. 507 μg/L, t = 3. 463, P = 0.001 ）. Twelve patients got a good result,22 fair, and 2 poor in the treatment group;while 6 patients got a good result, 21 fair, and 9 poor in the control group. The treatment group surpassed the control group in the total curative effect（ gt^atment gwup ~ 31.33, Rcontrol group ~ 41.67, Z = -2. 390,P = O. 017）. Conclusion：The JIEGUYAO pill can obviously increase the femoral BMD and ALP contents in the patients after hip hemiarthroplasty, and it has better preventative effects on periprosthetic osteoporosis compared with activated vitamin D
出处
《中医正骨》
2013年第9期19-21,共3页
The Journal of Traditional Chinese Orthopedics and Traumatology
基金
山东省科技发展计划项目(2010GFS10286)
关键词
骨质疏松
接骨药丸
关节成形术
置换
髋治疗
临床研究性
Osteoporosis
JIEGUYAO pill
Arthroplasty, replacement, hip
Therapies, investigational
